EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Diagnostic Value of Spinal Cord Lesion Metabolism on [ 18 F ] FDG PET / CT for the Classification of Myelopathy

Antoine Gavoille iD, Anthime Flaus iD, Matthieu Dietz, Julie Pique, Antoine Seyve, Pierre Lardeux, Romain Marignier, Marc Janier, Pascal Sève

European Journal of Neurology · 2026-07 · 33 (7)

DOI: 10.1111/ene.70667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 14.07.2026. Verfasst von Antoine Gavoille und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Centre de Référence des Maladies Inflammatoires Rares du…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Sarcoidosis, Myelitis, Central Nervous System Diseases. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction [ 18 F]FDG PET/CT scan is sometimes performed as part of the diagnostic evaluation of non‐compressive myelopathies, but the spinal cord lesion metabolism is not systematically evaluated. We aimed to investigate the diagnostic value of spinal cord lesion metabolism on [ 18 F]FDG PET/CT for differentiating inflammatory myelitis from neurosarcoidosis and tumoral lesions.

Methods

We conducted a retrospective cohort study of patients presenting with spinal cord lesions who underwent [ 18 F]FDG PET/CT. Patients were classified as primary inflammatory myelitis, neurosarcoidosis, tumoral lesions, or other etiologies. PET/CT examinations were reviewed by a nuclear medicine physician, masked to final diagnosis, who assessed the presence of hypermetabolism (qualitative analysis) and measured lesion SUV max , lesion‐to‐liver ratio, and level‐standardized Z ‐score to account for physiological uptake variability (quantitative analysis).

Results

A total of 106 patients were included: 60 (56.6%) with inflammatory myelitis, 20 (18.9%) with neurosarcoidosis, 10 (9.4%) with tumoral lesions, and 16 (15.1%) with other etiologies. Hypermetabolism was found in 80.0% of tumoral lesions, 50.0% of neurosarcoidosis, and 23.3% of inflammatory myelitis. PET/CT showed good performance in differentiating inflammatory myelitis or neurosarcoidosis from tumoral lesions using qualitative analysis (hypermetabolism: sensitivity 0.77, specificity 0.80, and 0.50, respectively) and quantitative analysis (SUV max : AUC 0.89 and 0.84, respectively). The performance of SUV max for distinguishing inflammatory myelitis from neurosarcoidosis was low (AUC 0.55), but improved with the lesion‐to‐liver ratio (AUC 0.64) and level‐standardized Z ‐score (AUC 0.65).

Conclusion

Spinal cord hypermetabolism on [ 18 F]FDG PET/CT demonstrated good performance for distinguishing tumoral lesions from inflammatory or neurosarcoidosis, but lower performance for differentiating inflammatory myelitis from neurosarcoidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographySarcoidosisMyelitisCentral Nervous System DiseasesSpinal CordSpinal Cord DiseasesSpinal Cord NeoplasmsHumansFemaleMaleFluorodeoxyglucose F18Retrospective StudiesMiddle AgedAgedAdultRadiopharmaceuticalsDiagnosis, Differential

Stichwörter der Autor:innen

[18F]FDG PET/CTmyelitismyelopathyneurosarcoidosisspinal cord tumor

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Hôpital Neurologique Pierre Werthei…
  • CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Université Lyon 1, Villeurbanne, France.
  • Service de Biostatistique-Bioinformatique, Hospices Civils de Lyon, Lyon, France.
  • Département de médecine nucléaire, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
  • Université Claude Bernard Lyon 1, Lyon, France.
  • Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Lyon, France.

ORCID-Profile: Antoine Gavoille, Anthime Flaus

Zitieren

APA

Gavoille, A., Flaus, A., Dietz, M., Pique, J., Seyve, A., Lardeux, P., Marignier, R., Janier, M., & Sève, P. (2026). Diagnostic Value of Spinal Cord Lesion Metabolism on [ 18 F ] FDG PET / CT for the Classification of Myelopathy. European Journal of Neurology, 33(7). https://doi.org/10.1111/ene.70667

Vancouver

Gavoille A, Flaus A, Dietz M, Pique J, Seyve A, Lardeux P, et al. Diagnostic Value of Spinal Cord Lesion Metabolism on [ 18 F ] FDG PET / CT for the Classification of Myelopathy. European Journal of Neurology. 2026;33(7). doi:10.1111/ene.70667

BibTeX
@article{Gavoille2026,
  author = {Gavoille, Antoine and Flaus, Anthime and Dietz, Matthieu and Pique, Julie and Seyve, Antoine and Lardeux, Pierre and Marignier, Romain and Janier, Marc and Sève, Pascal},
  title = {Diagnostic Value of Spinal Cord Lesion Metabolism on [ 18 F ] FDG PET / CT for the Classification of Myelopathy},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1111/ene.70667}
}
Kostenlos starten →